

Brian J Angus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8903747/publications.pdf>

Version: 2024-02-01

133
papers

19,443
citations

41258

49
h-index

15683

125
g-index

166
all docs

166
docs citations

166
times ranked

26768
citing authors

#	ARTICLE	IF	CITATIONS
1	Neurochemical abnormalities in chronic fatigue syndrome: a pilot magnetic resonance spectroscopy study at 7 Tesla. <i>Psychopharmacology</i> , 2022, 239, 163-171.	1.5	5
2	Mucosal-Associated Invariant T cells exhibit distinct functional signatures associated with protection against typhoid fever. <i>Cellular Immunology</i> , 2022, 378, 104572.	1.4	5
3	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	6.3	3,887
4	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	15.2	265
5	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278.	15.2	473
6	Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. <i>EClinicalMedicine</i> , 2021, 31, 100683.	3.2	435
7	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	6.3	979
8	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362.	6.3	540
9	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T _H 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	5.8	80
10	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	15.2	900
11	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 467-478.	6.3	2,080
12	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993.	6.3	1,196
13	Homologous and heterologous re-challenge with <i>Salmonella Typhi</i> and <i>Salmonella Paratyphi A</i> in a randomised controlled human infection model. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008783.	1.3	15
14	Investigation of the role of typhoid toxin in acute typhoid fever in a human challenge model. <i>Nature Medicine</i> , 2019, 25, 1082-1088.	15.2	33
15	Oral versus Intravenous Antibiotics for Bone and Joint Infection. <i>New England Journal of Medicine</i> , 2019, 380, 425-436.	13.9	548
16	Comparison of an ordinal endpoint to time-to-event, longitudinal, and binary endpoints for use in evaluating treatments for severe influenza requiring hospitalization. <i>Contemporary Clinical Trials Communications</i> , 2019, 15, 100401.	0.5	15
17	Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults. <i>Journal of Infection</i> , 2019, 78, 382-392.	1.7	42
18	Treatment responses to Azithromycin and Ciprofloxacin in uncomplicated <i>Salmonella Typhi</i> infection: A comparison of Clinical and Microbiological Data from a Controlled Human Infection Model. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007955.	1.3	21

#	ARTICLE	IF	CITATIONS
19	The Impact of Vaccination and Prior Exposure on Stool Shedding of Salmonella Typhi and Salmonella Paratyphi in 6 Controlled Human Infection Studies. <i>Clinical Infectious Diseases</i> , 2019, 68, 1265-1273.	2.9	26
20	Prime and target immunization protects against liver-stage malaria in mice. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	68
21	Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. <i>Npj Vaccines</i> , 2018, 3, 49.	2.9	51
22	Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic. <i>Clinical Infectious Diseases</i> , 2018, 67, 341-349.	2.9	6
23	Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μ L: secondary outcome results from a randomised controlled trial. <i>Lancet HIV</i> , 2017, 4, e105-e112.	2.1	44
24	Response to the editorial by Dr Geraghty. <i>Journal of Health Psychology</i> , 2017, 22, 1113-1117.	1.3	16
25	Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. <i>Lancet, The</i> , 2017, 390, 2472-2480.	6.3	251
26	Strategies for developing sustainable health research capacity in low and middle-income countries: a prospective, qualitative study investigating the barriers and enablers to locally led clinical trial conduct in Ethiopia, Cameroon and Sri Lanka. <i>BMJ Open</i> , 2017, 7, e017246.	0.8	52
27	Evaluation of the immunogenicity and impact on the latent HIV reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects. <i>Journal of the International AIDS Society</i> , 2017, 20, 21171.	1.2	36
28	Importance of Salmonella Typhi-Responsive CD8+ T Cell Immunity in a Human Typhoid Fever Challenge Model. <i>Frontiers in Immunology</i> , 2017, 8, 208.	2.2	30
29	Challenge of Humans with Wild-type Salmonella enterica Serovar Typhi Elicits Changes in the Activation and Homing Characteristics of Mucosal-Associated Invariant T Cells. <i>Frontiers in Immunology</i> , 2017, 8, 398.	2.2	47
30	Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009-2015. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx212.	0.4	16
31	Evaluation of the Clinical and Microbiological Response to Salmonella Paratyphi A Infection in the First Paratyphoid Human Challenge Model. <i>Clinical Infectious Diseases</i> , 2017, 64, 1066-1073.	2.9	60
32	Investigating Systemic Immunity to Typhoid and Paratyphoid Fever: Characterising the Response to Re-challenge in a Controlled Human Infection Model. <i>Open Forum Infectious Diseases</i> , 2017, 4, S227-S228.	0.4	4
33	Oral Challenge with Wild-Type Salmonella Typhi Induces Distinct Changes in B Cell Subsets in Individuals Who Develop Typhoid Disease. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004766.	1.3	20
34	Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004926.	1.3	67
35	Interferon-driven alterations of the host's amino acid metabolism in the pathogenesis of typhoid fever. <i>Journal of Experimental Medicine</i> , 2016, 213, 1061-1077.	4.2	45
36	Salmonella Typhi-specific multifunctional CD8+ T cells play a dominant role in protection from typhoid fever in humans. <i>Journal of Translational Medicine</i> , 2016, 14, 62.	1.8	67

#	ARTICLE	IF	CITATIONS
37	Safety and Immunogenicity of Novel Adenovirus Type 26 and Modified Vaccinia Ankara Vectors for Ebola Vaccines. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1610.	3.8	266
38	British HIV Association guidelines for the treatment of HIV-positive adults with antiretroviral therapy 2015. <i>HIV Medicine</i> , 2016, 17, s2-s104.	1.0	78
39	Live attenuated oral vaccine, age and anti-Vi antibody status at baseline significantly affect attack rate in a human <i>Salmonella Typhi</i> challenge model. <i>Journal of Infection</i> , 2015, 71, 689.	1.7	0
40	Oral versus intravenous antibiotic treatment for bone and joint infections (OVIVA): study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 583.	0.7	48
41	Oral Wild-Type <i>Salmonella Typhi</i> Challenge Induces Activation of Circulating Monocytes and Dendritic Cells in Individuals Who Develop Typhoid Disease. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003837.	1.3	18
42	Activation of <i>Salmonella Typhi</i> -Specific Regulatory T Cells in Typhoid Disease in a Wild-Type <i>S. Typhi</i> Challenge Model. <i>PLoS Pathogens</i> , 2015, 11, e1004914.	2.1	50
43	Understanding paratyphoid infection: study protocol for the development of a human model of <i>Salmonella enterica</i> serovar Paratyphi A challenge in healthy adult volunteers. <i>BMJ Open</i> , 2015, 5, e007481-e007481.	0.8	16
44	Chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. <i>Science Translational Medicine</i> , 2015, 7, 300ra126.	5.8	109
45	The VACS Index Accurately Predicts Mortality and Treatment Response among Multi-Drug Resistant HIV Infected Patients Participating in the Options in Management with Antiretrovirals (OPTIMA) Study. <i>PLoS ONE</i> , 2014, 9, e92606.	1.1	23
46	Reply to Farmakiotis et al. <i>Clinical Infectious Diseases</i> , 2014, 59, 1198-1199.	2.9	0
47	An Outpatient, Ambulant-Design, Controlled Human Infection Model Using Escalating Doses of <i>Salmonella Typhi</i> Challenge Delivered in Sodium Bicarbonate Solution. <i>Clinical Infectious Diseases</i> , 2014, 58, 1230-1240.	2.9	126
48	Evaluation of the Immunogenicity and Impact on the Latent HIV-1 Reservoir of an HIV Conserved Region Vaccine, MVA.HIVconsrv, in HAART-treated Subjects. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A190-A190.	0.5	1
49	Advancing the management and control of typhoid fever: A review of the historical role of human challenge studies. <i>Journal of Infection</i> , 2014, 68, 405-418.	1.7	40
50	Novel anti-malarial combinations and their toxicity. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 299-316.	1.3	26
51	Adverse events and deterioration reported by participants in the PACE trial of therapies for chronic fatigue syndrome. <i>Journal of Psychosomatic Research</i> , 2014, 77, 20-26.	1.2	41
52	Prognostic indicators in adults hospitalized with falciparum malaria in Western Thailand. <i>Malaria Journal</i> , 2013, 12, 229.	0.8	27
53	Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients. <i>Histopathology</i> , 2013, 63, 788-801.	1.6	25
54	Barriers and enablers of locally led clinical trials in Ethiopia and Cameroon: a prospective, qualitative study. <i>Lancet</i> , The, 2013, 382, 14.	6.3	12

#	ARTICLE	IF	CITATIONS
55	Improved quantification of HIV-1-infected CD4+ T cells using an optimised method of intracellular HIV-1 gag p24 antigen detection. <i>Journal of Immunological Methods</i> , 2013, 391, 174-178.	0.6	26
56	Cost-Effectiveness of Newer Antiretroviral Drugs in Treatment-Experienced Patients With Multidrug-Resistant HIV Disease. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 382-391.	0.9	11
57	Understanding the investigators: a qualitative study investigating the barriers and enablers to the implementation of local investigator-initiated clinical trials in Ethiopia. <i>BMJ Open</i> , 2013, 3, e003616.	0.8	29
58	Sequence Analysis of <i>In Vivo</i> Defective Interfering-Like RNA of Influenza A H1N1 Pandemic Virus. <i>Journal of Virology</i> , 2013, 87, 8064-8074.	1.5	144
59	Comprehensive Cardiac Magnetic Resonance Imaging and Spectroscopy Reveal a High Burden of Myocardial Disease in HIV Patients. <i>Circulation</i> , 2013, 128, 814-822.	1.6	160
60	Emergence of a distinct HIV-specific IL-10-producing CD8 ⁺ T-cell subset with immunomodulatory functions during chronic HIV infection. <i>European Journal of Immunology</i> , 2013, 43, 2875-2885.	1.6	4
61	Biomarkers and Bacterial Pneumonia Risk in Patients with Treated HIV Infection: A Case-Control Study. <i>PLoS ONE</i> , 2013, 8, e56249.	1.1	18
62	The Association between Serum Biomarkers and Disease Outcome in Influenza A(H1N1)pdm09 Virus Infection: Results of Two International Observational Cohort Studies. <i>PLoS ONE</i> , 2013, 8, e57121.	1.1	54
63	Antiviral Inhibitory Capacity of CD8 ⁺ T cells Predicts the Rate of CD4 ⁺ T-Cell Decline in HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2012, 206, 552-561.	1.9	74
64	Fidaxomicin Versus Vancomycin for <i>Clostridium difficile</i> Infection: Meta-analysis of Pivotal Randomized Controlled Trials. <i>Clinical Infectious Diseases</i> , 2012, 55, S93-S103.	2.9	228
65	Pneumococcal Conjugate and Plain Polysaccharide Vaccines Have Divergent Effects on Antigen-Specific B Cells. <i>Journal of Infectious Diseases</i> , 2012, 205, 1408-1416.	1.9	235
66	Effects of Hydroxychloroquine on Immune Activation and Disease Progression Among HIV-Infected Patients Not Receiving Antiretroviral Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 353-61.	3.8	146
67	Polymorphous lymphoproliferative disorder with Hodgkin-like features in common γ -chain-deficient severe combined immunodeficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 533-535.	1.5	16
68	Surveillance of illness associated with pandemic (H1N1) 2009 virus infection among adults using a global clinical site network approach: The INSIGHT FLU 002 and FLU 003 studies. <i>Vaccine</i> , 2011, 29, B56-B62.	1.7	14
69	Results of Antiretroviral Treatment Interruption and Intensification in Advanced Multi-Drug Resistant HIV Infection from the OPTIMA Trial. <i>PLoS ONE</i> , 2011, 6, e14764.	1.1	16
70	Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT). <i>HIV Medicine</i> , 2011, 12, 219-227.	1.0	8
71	British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. <i>HIV Medicine</i> , 2011, 12, 1-5.	1.0	99
72	Poor quality vital anti-malarials in Africa - an urgent neglected public health priority. <i>Malaria Journal</i> , 2011, 10, 352.	0.8	111

#	ARTICLE	IF	CITATIONS
73	A Randomized Study Comparing Combined Pneumococcal Conjugate and Polysaccharide Vaccination Schedules in Adults. <i>Clinical Infectious Diseases</i> , 2011, 52, 736-742.	2.9	97
74	Mortality after Fluid Bolus in African Children with Severe Infection. <i>New England Journal of Medicine</i> , 2011, 364, 2483-2495.	13.9	1,871
75	A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines. <i>International Journal of Oncology</i> , 2010, 37, 367-76.	1.4	22
76	Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. <i>Aids</i> , 2010, 24, 697-706.	1.0	150
77	Clinical Research in Resource-Limited Settings: Enhancing Research Capacity and Working Together to Make Trials Less Complicated. <i>PLoS Neglected Tropical Diseases</i> , 2010, 4, e619.	1.3	62
78	Artemisinin combination therapy for vivax malaria. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 405-416.	4.6	204
79	Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA Trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 54, 160-166.	0.9	16
80	Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics. <i>International Journal of Oncology</i> , 2009, 35, 961-71.	1.4	15
81	Interruption of antiretroviral therapy is associated with increased plasma cystatin C. <i>Aids</i> , 2009, 23, 71-82.	1.0	47
82	Travel medicine has come of age and a new examination marks the 21st birthday. <i>Travel Medicine and Infectious Disease</i> , 2009, 7, 179-180.	1.5	3
83	TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals. <i>Aids</i> , 2008, 22, 737-740.	1.0	6
84	Micro-vessel density and the expression of vascular endothelial growth factor (VEGF) and platelet-derived endothelial cell growth factor (PDEGF) in classical Hodgkin lymphoma (HL). <i>Leukemia and Lymphoma</i> , 2006, 47, 223-230.	0.6	34
85	Interleukin 2 treatment in HIV-1 infection. <i>Lancet</i> , The, 2006, 367, 1054-1055.	6.3	2
86	Early treatment failure in severe malaria resulting from abnormally low plasma quinine concentrations. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2006, 100, 184-186.	0.7	13
87	Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. <i>Blood</i> , 2005, 106, 2444-2451.	0.6	184
88	Omenn's syndrome occurring in patients without mutations in recombination activating genes. <i>Clinical Immunology</i> , 2005, 116, 246-256.	1.4	28
89	Dysuria and a headache. <i>Lancet</i> , The, 2004, 364, 1554.	6.3	1
90	An epidemiologic study of index and family infectious mononucleosis and adult Hodgkin's disease (HD): Evidence for a specific association with EBV+ve HD in young adults. <i>International Journal of Cancer</i> , 2003, 107, 298-302.	2.3	51

#	ARTICLE	IF	CITATIONS
91	Randomized Comparison of Artesunate and Quinine in the Treatment of Severe Falciparum Malaria. <i>Clinical Infectious Diseases</i> , 2003, 37, 7-16.	2.9	81
92	Comparative Assessment Expression of the Inhibitor of Growth 1 Gene (ING1) in Normal and Neoplastic Tissues. <i>Hybridoma</i> , 2002, 21, 1-10.	0.6	30
93	Oral Artesunate Dose-Response Relationship in Acute Falciparum Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 778-782.	1.4	68
94	CD Rom Review. <i>Tropical Doctor</i> , 2002, 32, 126-126.	0.2	0
95	Hodgkin's disease in the elderly: a population-based study. <i>British Journal of Haematology</i> , 2002, 119, 432-440.	1.2	130
96	Protein and energy metabolism in chronic bacterial infection: studies in melioidosis. <i>Clinical Science</i> , 2001, 100, 101-110.	1.8	8
97	Protein and energy metabolism in chronic bacterial infection: studies in melioidosis. <i>Clinical Science</i> , 2001, 100, 101.	1.8	8
98	A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria. <i>British Journal of Clinical Pharmacology</i> , 2001, 52, 655-661.	1.1	33
99	Cutaneous Tuberculosis of the Penis and Sexual Transmission of Tuberculosis Confirmed by Molecular Typing. <i>Clinical Infectious Diseases</i> , 2001, 33, e132-e134.	2.9	57
100	Malaria on the World Wide Web. <i>Clinical Infectious Diseases</i> , 2001, 33, 651-661.	2.9	7
101	Molecular analysis reveals somatically mutated and unmutated clonal and oligoclonal B cells in T-cell-rich B-cell lymphoma. <i>Journal of Pathology</i> , 2000, 192, 479-487.	2.1	2
102	Primary treatment of low-grade non-Hodgkin's lymphoma using an all oral anthracycline-containing regimen, chlorambucil, idarubicin, dexamethasone (CID) - a phase II study. <i>Cancer Chemotherapy and Pharmacology</i> , 2000, 46, 63-68.	1.1	3
103	Glucose and Lactate Kinetics in Children with Severe Malaria. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 1569-1576.	1.8	61
104	A Double-Blind Placebo-Controlled Study of an Infusion of Lexipafant (Platelet-Activating Factor) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2. 693-696.	1.4	49
105	Comparison of Imipenem and Ceftazidime as Therapy for Severe Melioidosis. <i>Clinical Infectious Diseases</i> , 1999, 29, 381-387.	2.9	167
106	A Comparison of Chloramphenicol, Trimethoprimâ€Sulfamethoxazole, and Doxycycline with Doxycycline Alone as Maintenance Therapy for Melioidosis. <i>Clinical Infectious Diseases</i> , 1999, 29, 375-380.	2.9	88
107	Expression of growth regulatory genes in a SCID mouse-human model of intestinal epithelial regeneration. , 1999, 187, 229-236.		13
108	NCL-CD10â€270: A New Monoclonal Antibody Recognizing CD10 in Paraffin-Embedded Tissue. <i>American Journal of Pathology</i> , 1999, 154, 77-82.	1.9	137

#	ARTICLE	IF	CITATIONS
109	Cyclin D3 Expression, Cell Proliferation and Pathological Stage of Human Primary Colorectal Cancer. <i>Oncology</i> , 1999, 56, 66-72.	0.9	8
110	In Vivo Removal of Malaria Parasites From Red Blood Cells Without Their Destruction in Acute Falciparum Malaria. <i>Blood</i> , 1997, 90, 2037-2040.	0.6	108
111	Alpha interferon gene deletions in post-transplant lymphoma. <i>British Journal of Haematology</i> , 1997, 98, 1002-1003.	1.2	10
112	Plasma nitrogen oxides and blood lactate concentrations in Ghanaian children with malaria. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1997, 91, 298-302.	0.7	34
113	THE PATHOLOGICAL AND BIOLOGICAL NATURE OF SCREEN-DETECTED BREAST CARCINOMAS: A MORPHOLOGICAL AND IMMUNOHISTOCHEMICAL STUDY. , 1997, 182, 29-35.		33
114	New monoclonal antibodies to oestrogen and progesterone receptors effective for paraffin section immunohistochemistry. , 1997, 183, 228-232.		59
115	Determination of HLA-A*02 antigen status in Hodgkin's disease and analysis of an HLA-A*02-restricted epitope of the Epstein-Barr virus LMP-2 protein. , 1997, 72, 614-618.		11
116	New monoclonal antibodies to oestrogen and progesterone receptors effective for paraffin section immunohistochemistry. , 1997, 183, 228.		4
117	Prognostic Significance of Reduced Red Blood Cell Deformability in Severe Falciparum Malaria. <i>American Journal of Tropical Medicine and Hygiene</i> , 1997, 57, 507-511.	0.6	131
118	Response of PUVA-induced keratoses to etretinate. <i>Journal of the American Academy of Dermatology</i> , 1996, 35, 120-123.	0.6	7
119	RETINOBLASTOMA PROTEIN IN HUMAN BREAST CARCINOMA: IMMUNOHISTOCHEMICAL STUDY USING A NEW MONOCLONAL ANTIBODY EFFECTIVE ON ROUTINELY PROCESSED TISSUES. , 1996, 180, 65-70.		24
120	Short Report: Rosette Formation in Plasmodium ovale Infection. <i>American Journal of Tropical Medicine and Hygiene</i> , 1996, 55, 560-561.	0.6	40
121	Loss of heterozygosity in sporadic primary cutaneous melanoma. <i>Genes Chromosomes and Cancer</i> , 1995, 12, 152-156.	1.5	93
122	A flow cytometric study of c-erbB-3 expression in breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 1995, 41, 280-286.	2.0	5
123	The relationship between flow-cytometric and immunohistochemically detected c-erbB-2 expression, grade and DNA ploidy in breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 1995, 41, 137-145.	2.0	8
124	p53 expression measured by flow cytometry. A comparison of three monoclonal antibodies and the relationship with grade and DNA ploidy in breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 1995, 41, 146-150.	2.0	1
125	A flow cytometric study of c-erbB-3 expression in breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 1995, 41, 280-286.	2.0	1
126	A family with adult-onset cerebral adrenoleucodystrophy. <i>Journal of Neurology</i> , 1994, 241, 497-499.	1.8	23

#	ARTICLE	IF	CITATIONS
127	Retinoblastoma and p53 gene expression related to relapse and survival in human breast cancer: An immunohistochemical study. <i>Journal of Pathology</i> , 1992, 168, 23-28.	2.1	72
128	Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: An immunohistochemical study using monoclonal antibody NCL-CB11. <i>Journal of Pathology</i> , 1991, 163, 105-110.	2.1	75
129	NCL-CB11, a new monoclonal antibody recognizing the internal domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded tissue. <i>Journal of Pathology</i> , 1990, 161, 15-25.	2.1	108
130	Oestrogen receptor and oestrogen regulated proteins in human breast cancer: A review.. <i>Keio Journal of Medicine</i> , 1989, 38, 241-261.	0.5	8
131	Cytokeratins in cervical dysplasia and neoplasia: A comparative study of immunohistochemical staining using monoclonal antibodies NCL-5D3, CAM 5A2, and PKK1. <i>Journal of Pathology</i> , 1988, 155, 71-75.	2.1	39
132	Relationships between oestrogen receptor, epidermal growth factor receptor, ER-D5, and P24 oestrogen regulated protein in human breast cancer. <i>Journal of Pathology</i> , 1988, 155, 143-150.	2.1	38
133	A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2. <i>International Journal of Oncology</i> , 0, , .	1.4	3